[
  {
    "ticker": "LLY",
    "name": "Lilly (Eli)",
    "marketCap": 940920995840,
    "revenueGrowth": 0.539,
    "debtToEquity": 178.516,
    "trailingPE": 51.55206,
    "momentum_2m": 0.4281230006530785,
    "momentum_1w": 0.03277861904260293,
    "FundamentalFilterRating": 66,
    "price": 1049.5999755859375,
    "RSI (14)": 93.06,
    "EMA (20)": 947.25,
    "MACD (12,26,9)": 57.6125,
    "MACD_Signal (12,26,9)": 46.0379,
    "percent_change": 1.9,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 69.2,
    "AITicker": "LLY, známa ako Eli Lilly, je farmaceutická spoločnosť zameraná na vývoj a predaj liekov v sektore zdravotnej starostlivosti.",
    "AIComment": "Akcia LLY ukazuje silný krátkodobý rastový potenciál, napriek negatívnemu trendu na trhu a neutrálnemu trendu v sektore zdravotnej starostlivosti. Vysoký RSI naznačuje možné prekúpenie, čo by mohlo viesť k krátkodobej korekcii. Avšak, silný rast príjmov a pozitívny sentiment správ podporujú možnosť udržania momentum.",
    "AIScore": 75,
    "SL": 1018.11,
    "TP": 1102.08,
    "SL10": 9.7,
    "TP10": 10.5
  },
  {
    "ticker": "HCA",
    "name": "HCA Healthcare",
    "marketCap": 112564912128,
    "revenueGrowth": 0.096,
    "debtToEquity": null,
    "trailingPE": 18.588099,
    "momentum_2m": 0.198926946671796,
    "momentum_1w": 0.015730268443350237,
    "FundamentalFilterRating": 83,
    "price": 481.05999755859375,
    "RSI (14)": 60.38,
    "EMA (20)": 466.11,
    "MACD (12,26,9)": 9.1772,
    "MACD_Signal (12,26,9)": 8.7761,
    "percent_change": 0.61,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 83.2,
    "AITicker": "HCA Healthcare is a healthcare provider, operating hospitals and healthcare facilities primarily in the United States.",
    "AIComment": "Despite a recent downturn in the broader market, HCA Healthcare shows resilience with a positive momentum and a strong news sentiment. The stock's performance is bolstered by a robust RSI and favorable MACD values, suggesting potential for short-term gains. However, the neutral sector trend and recent market volatility could moderate the upside.",
    "AIScore": 72,
    "SL": 466.63,
    "TP": 505.11,
    "SL10": 9.7,
    "TP10": 10.5
  },
  {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals",
    "marketCap": 74482671616,
    "revenueGrowth": 0.009,
    "debtToEquity": 8.739,
    "trailingPE": 16.836367,
    "momentum_2m": 0.19586483587863723,
    "momentum_1w": 0.030848486476323433,
    "FundamentalFilterRating": 66,
    "price": 702.75,
    "RSI (14)": 65.76,
    "EMA (20)": 661.32,
    "MACD (12,26,9)": 30.1946,
    "MACD_Signal (12,26,9)": 25.2162,
    "percent_change": -3.11,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 80.3,
    "AITicker": "Regeneron Pharmaceuticals, a biotechnology company, focuses on the discovery, development, and commercialization of treatments for serious medical conditions.",
    "AIComment": "Despite a recent market downturn, Regeneron Pharmaceuticals shows potential for short-term trading due to its positive momentum indicators and strong news sentiment. The stock's RSI is moderately high, suggesting some overbought conditions, but the positive MACD divergence indicates underlying strength. The neutral sector trend and slight revenue growth also support a cautiously optimistic outlook for the next 2-10 days.",
    "AIScore": 68,
    "SL": 681.67,
    "TP": 737.89,
    "SL10": 9.7,
    "TP10": 10.5
  },
  {
    "ticker": "DHR",
    "name": "Danaher Corporation",
    "marketCap": 159257034752,
    "revenueGrowth": 0.044,
    "debtToEquity": 35.544,
    "trailingPE": 45.669407,
    "momentum_2m": 0.08025649516296052,
    "momentum_1w": 0.013719279167551557,
    "FundamentalFilterRating": 66,
    "price": 222.41000366210938,
    "RSI (14)": 64.16,
    "EMA (20)": 217.18,
    "MACD (12,26,9)": 2.6676,
    "MACD_Signal (12,26,9)": 1.8479,
    "percent_change": -1.37,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 100.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 88.7,
    "AITicker": "Danaher Corporation is a global science and technology innovator focused on helping customers solve complex challenges in the healthcare sector.",
    "AIComment": "Despite a recent downturn in the broader market, Danaher Corporation shows resilience with a positive momentum over the last two months and a stable week. The stock's technical indicators such as a higher RSI and positive MACD values suggest strength, but the recent market and sector trends could pose risks. Caution is advised for trading in the next 2-10 days due to potential market volatility.",
    "AIScore": 65,
    "SL": 215.74,
    "TP": 231.31,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "FANG",
    "name": "Diamondback Energy",
    "marketCap": 43043692544,
    "revenueGrowth": 0.42,
    "debtToEquity": 35.66,
    "trailingPE": 10.441714,
    "momentum_2m": 0.039971107846324294,
    "momentum_1w": 0.02424746377942677,
    "FundamentalFilterRating": 83,
    "price": 148.69000244140625,
    "RSI (14)": 61.67,
    "EMA (20)": 144.28,
    "MACD (12,26,9)": 1.9289,
    "MACD_Signal (12,26,9)": 1.1726,
    "percent_change": -0.59,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Energy",
    "sector_name": "XLE",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -1.2958492607212047,
    "sector_change_5d": -0.4099753424731678,
    "sector_change_20d": 2.3690138147649087,
    "sector_trend": "neutral",
    "OverallRating": 83.2,
    "AITicker": "Diamondback Energy, Inc. (FANG) is an energy company primarily engaged in hydrocarbon exploration.",
    "AIComment": "Despite a recent downturn in the broader market, Diamondback Energy shows resilience with a positive momentum and a strong news sentiment. The neutral sector trend and the company's solid fundamentals, including a reasonable debt-to-equity ratio and a healthy RSI, suggest it might withstand short-term market volatility. However, caution is advised due to the overall market decline.",
    "AIScore": 65,
    "SL": 144.23,
    "TP": 154.64,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "MCK",
    "name": "McKesson Corporation",
    "marketCap": 106033963008,
    "revenueGrowth": 0.101,
    "debtToEquity": null,
    "trailingPE": 26.664686,
    "momentum_2m": 0.2541720899848019,
    "momentum_1w": 0.01393989973609866,
    "FundamentalFilterRating": 83,
    "price": 852.469970703125,
    "RSI (14)": 60.31,
    "EMA (20)": 836.22,
    "MACD (12,26,9)": 15.2346,
    "MACD_Signal (12,26,9)": 14.7179,
    "percent_change": -0.96,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 83.2,
    "AITicker": "McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.",
    "AIComment": "Despite a recent downturn in the broader market, McKesson Corporation shows resilience with a positive momentum over the last two months and a stable week-over-week performance. The stock's technical indicators such as a higher RSI and MACD above its signal line suggest strength. However, the negative market trend and neutral sector outlook may limit upside potential in the short term.",
    "AIScore": 65,
    "SL": 826.9,
    "TP": 895.09,
    "SL10": 9.7,
    "TP10": 10.5
  },
  {
    "ticker": "BKR",
    "name": "Baker Hughes",
    "marketCap": 47838797824,
    "revenueGrowth": 0.015,
    "debtToEquity": 33.042,
    "trailingPE": 16.717241,
    "momentum_2m": 0.09584544616882584,
    "momentum_1w": 0.019987392958933814,
    "FundamentalFilterRating": 66,
    "price": 48.47999954223633,
    "RSI (14)": 50.65,
    "EMA (20)": 47.73,
    "MACD (12,26,9)": 0.4237,
    "MACD_Signal (12,26,9)": 0.4193,
    "percent_change": 0.87,
    "TechFilterRating": 100.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Energy",
    "sector_name": "XLE",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -1.2958492607212047,
    "sector_change_5d": -0.4099753424731678,
    "sector_change_20d": 2.3690138147649087,
    "sector_trend": "neutral",
    "OverallRating": 80.3,
    "AITicker": "Baker Hughes is an energy technology company, primarily engaged in the oilfield services and equipment sector.",
    "AIComment": "Despite a general market downturn over the past 5 days, Baker Hughes shows resilience with a positive momentum and a slight increase in price. The neutral sector trend and positive news sentiment suggest stability, but the overall market negativity could limit short-term gains. The technical indicators like MACD above its signal and a stable RSI suggest a balanced but cautious trading outlook.",
    "AIScore": 65,
    "SL": 47.03,
    "TP": 50.42,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "JNJ",
    "name": "Johnson & Johnson",
    "marketCap": 487906344960,
    "revenueGrowth": 0.068,
    "debtToEquity": 57.766,
    "trailingPE": 19.566183,
    "momentum_2m": 0.147430382479532,
    "momentum_1w": 0.04177167108741653,
    "FundamentalFilterRating": 83,
    "price": 202.50999450683594,
    "RSI (14)": 81.22,
    "EMA (20)": 193.66,
    "MACD (12,26,9)": 1.9962,
    "MACD_Signal (12,26,9)": 0.3337,
    "percent_change": 1.25,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 77.7,
    "AITicker": "Johnson & Johnson, a major player in the healthcare sector, primarily focuses on manufacturing pharmaceuticals, medical devices, and consumer health products.",
    "AIComment": "Despite a recent downturn in the overall market, Johnson & Johnson shows strong individual performance with a high RSI indicating potential overbought conditions, which could lead to a price pullback in the short term. However, positive momentum and robust news sentiment suggest resilience. Caution is advised due to the mixed signals from market and sector trends.",
    "AIScore": 65,
    "SL": 196.43,
    "TP": 210.61,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "BIIB",
    "name": "Biogen",
    "marketCap": 24635711488,
    "revenueGrowth": 0.028,
    "debtToEquity": 36.194,
    "trailingPE": 15.308112,
    "momentum_2m": 0.22827670550336476,
    "momentum_1w": 0.039943009158391884,
    "FundamentalFilterRating": 66,
    "price": 167.92999267578125,
    "RSI (14)": 73.98,
    "EMA (20)": 158.35,
    "MACD (12,26,9)": 5.092,
    "MACD_Signal (12,26,9)": 3.7169,
    "percent_change": -0.53,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 83.3,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 74.8,
    "AITicker": "Biogen je biotechnologická spoločnosť zameraná na vývoj liekov pre neurologické a neurodegeneratívne ochorenia.",
    "AIComment": "Biogen ukazuje silný krátkodobý rastový potenciál s vysokým RSI a pozitívnym MACD nad signálom, čo naznačuje býčiu dynamiku. Avšak, negatívny trhový trend a neutrálny sektorový trend môžu obmedziť rastový potenciál. Vhodné pre opatrných investorov s dôrazom na monitorovanie trhových podmienok.",
    "AIScore": 65,
    "SL": 162.89,
    "TP": 174.65,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "UHS",
    "name": "Universal Health Services",
    "marketCap": 14505803776,
    "revenueGrowth": 0.134,
    "debtToEquity": 70.037,
    "trailingPE": 10.843958,
    "momentum_2m": 0.25759906061493587,
    "momentum_1w": -0.0021013734847508125,
    "FundamentalFilterRating": 66,
    "price": 227.94000244140625,
    "RSI (14)": 62.34,
    "EMA (20)": 222.67,
    "MACD (12,26,9)": 4.4781,
    "MACD_Signal (12,26,9)": 4.4578,
    "percent_change": -0.39,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 72.0,
    "AITicker": "Universal Health Services (UHS) is a healthcare provider, offering acute care hospital services and behavioral health services.",
    "AIComment": "Despite a recent downturn in the broader market, UHS shows resilience with a positive revenue growth and a stable debt-to-equity ratio. The stock's technical indicators such as a positive MACD and a RSI of 62.34 suggest strength, but the slight negative momentum over the past week and a neutral sector trend might limit upside potential in the short term. The positive news sentiment is encouraging, yet the market's negative trend could pose risks.",
    "AIScore": 65,
    "SL": 221.1,
    "TP": 239.34,
    "SL10": 9.7,
    "TP10": 10.5
  },
  {
    "ticker": "IQV",
    "name": "IQVIA",
    "marketCap": 37036843008,
    "revenueGrowth": 0.052,
    "debtToEquity": 242.366,
    "trailingPE": 29.955921,
    "momentum_2m": 0.15828718624947058,
    "momentum_1w": -0.015393014669106475,
    "FundamentalFilterRating": 66,
    "price": 217.47999572753906,
    "RSI (14)": 51.72,
    "EMA (20)": 216.35,
    "MACD (12,26,9)": 1.1558,
    "MACD_Signal (12,26,9)": 0.9541,
    "percent_change": 0.09,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 72.0,
    "AITicker": "IQVIA is a healthcare company specializing in analytics, technology solutions, and clinical research.",
    "AIComment": "IQVIA shows a mixed short-term trading outlook. The overall market is trending down, which could negatively impact the stock. However, the healthcare sector remains neutral, and IQVIA's technical indicators like a positive MACD above its signal and a stable RSI suggest some resilience. The positive news sentiment and recent revenue growth also support potential stability.",
    "AIScore": 58,
    "SL": 212.02,
    "TP": 228.35,
    "SL10": 9.75,
    "TP10": 10.5
  },
  {
    "ticker": "CTRA",
    "name": "Coterra",
    "marketCap": 19658485760,
    "revenueGrowth": 0.349,
    "debtToEquity": 27.957,
    "trailingPE": 11.925925,
    "momentum_2m": 0.08697605461512503,
    "momentum_1w": -0.005789182674912796,
    "FundamentalFilterRating": 66,
    "price": 25.760000228881836,
    "RSI (14)": 70.89,
    "EMA (20)": 25.23,
    "MACD (12,26,9)": 0.7217,
    "MACD_Signal (12,26,9)": 0.6896,
    "percent_change": -1.57,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 91.7,
    "social_sentiment_percent": null,
    "sector": "Energy",
    "sector_name": "XLE",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -1.2958492607212047,
    "sector_change_5d": -0.4099753424731678,
    "sector_change_20d": 2.3690138147649087,
    "sector_trend": "neutral",
    "OverallRating": 77.6,
    "AITicker": "Coterra is an energy company involved in the exploration and production of oil and natural gas.",
    "AIComment": "Despite a recent market downturn, Coterra's strong news sentiment and positive MACD values suggest potential resilience. However, the overall negative market trend and slight weekly momentum loss could limit short-term gains. Caution is advised due to mixed signals.",
    "AIScore": 55,
    "SL": 24.99,
    "TP": 26.53,
    "SL10": 9.7,
    "TP10": 10.3
  },
  {
    "ticker": "OKE",
    "name": "Oneok",
    "marketCap": 43736551424,
    "revenueGrowth": 0.719,
    "debtToEquity": 152.218,
    "trailingPE": 12.766543,
    "momentum_2m": -0.052212714912702185,
    "momentum_1w": 0.007982516838649145,
    "FundamentalFilterRating": 66,
    "price": 69.44999694824219,
    "RSI (14)": 66.83,
    "EMA (20)": 68.25,
    "MACD (12,26,9)": 0.586,
    "MACD_Signal (12,26,9)": 0.3132,
    "percent_change": 0.03,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Energy",
    "sector_name": "XLE",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -1.2958492607212047,
    "sector_change_5d": -0.4099753424731678,
    "sector_change_20d": 2.3690138147649087,
    "sector_trend": "neutral",
    "OverallRating": 69.2,
    "AITicker": "Oneok, Inc. is a midstream service provider in the energy sector, primarily engaged in gathering, processing, storage, and transportation of natural gas.",
    "AIComment": "Given the recent market downturn and a neutral sector trend, Oneok's short-term outlook is mixed. The stock shows resilience with a positive momentum over the past week and a strong news sentiment, which could buffer against broader market weaknesses. However, the high debt-to-equity ratio and slight negative momentum over the past two months suggest potential volatility.",
    "AIScore": 55,
    "SL": 67.37,
    "TP": 72.23,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "EW",
    "name": "Edwards Lifesciences",
    "marketCap": 50502344704,
    "revenueGrowth": 0.147,
    "debtToEquity": 6.862,
    "trailingPE": 37.72807,
    "momentum_2m": 0.05844715388462185,
    "momentum_1w": 0.005141327443300536,
    "FundamentalFilterRating": 66,
    "price": 86.0199966430664,
    "RSI (14)": 60.13,
    "EMA (20)": 83.01,
    "MACD (12,26,9)": 2.1765,
    "MACD_Signal (12,26,9)": 2.1885,
    "percent_change": 2.36,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 61.1,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 67.4,
    "AITicker": "Edwards Lifesciences is a healthcare company specializing in artificial heart valves and hemodynamic monitoring.",
    "AIComment": "Despite a recent positive price momentum and a strong news sentiment, the broader market downtrend and a neutral sector trend may limit upside potential for Edwards Lifesciences in the short term. The stock's technical indicators like a slightly positive MACD but close MACD and Signal lines suggest a cautious approach. The RSI at 60.13 indicates neither overbought nor oversold conditions, providing a neutral outlook.",
    "AIScore": 55,
    "SL": 83.44,
    "TP": 89.46,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "MRK",
    "name": "Merck & Co.",
    "marketCap": 237414318080,
    "revenueGrowth": 0.037,
    "debtToEquity": 79.708,
    "trailingPE": 12.572752,
    "momentum_2m": 0.1294141899905048,
    "momentum_1w": 0.03936584170202995,
    "FundamentalFilterRating": 83,
    "price": 95.05000305175781,
    "RSI (14)": 72.78,
    "EMA (20)": 89.8,
    "MACD (12,26,9)": 2.1326,
    "MACD_Signal (12,26,9)": 1.1318,
    "percent_change": -1.43,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 77.7,
    "AITicker": "Merck & Co., známa farmaceutická spoločnosť, sa zameriava na vývoj a distribúciu liekov a vakcín.",
    "AIComment": "Merck & Co. vykazuje silný technický profil s RSI nad 70, čo naznačuje možnú prekúpenosť, a pozitívny MACD nad signálom. Avšak, súčasný trhový trend je klesajúci a sektor zdravotníctva je neutrálny, čo môže obmedziť krátkodobý rast akcie. Vzhľadom na tieto faktory a nedávny pokles ceny o 1.43%, by mohlo byť rizikové investovať do tejto akcie na obdobie 2-10 dní.",
    "AIScore": 45,
    "SL": 92.2,
    "TP": 98.85,
    "SL10": 9.7,
    "TP10": 10.4
  },
  {
    "ticker": "PODD",
    "name": "Insulet Corporation",
    "marketCap": 24381157376,
    "revenueGrowth": 0.299,
    "debtToEquity": 77.711,
    "trailingPE": 100.97958,
    "momentum_2m": 0.043787479634944226,
    "momentum_1w": 0.028262644333133746,
    "FundamentalFilterRating": 66,
    "price": 346.3599853515625,
    "RSI (14)": 74.26,
    "EMA (20)": 328.0,
    "MACD (12,26,9)": 3.18,
    "MACD_Signal (12,26,9)": 0.792,
    "percent_change": 3.87,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 69.2,
    "AITicker": "Insulet Corporation, a healthcare company, specializes in manufacturing wearable insulin delivery systems.",
    "AIComment": "Despite a recent positive performance with a 3.87% price increase and strong momentum indicators, the broader market downtrend and neutral sector sentiment suggest potential volatility for Insulet Corporation in the short term. The high RSI of 74.26 indicates the stock might be overbought, which could lead to a price correction. Caution is advised for trading this stock in the next 2-10 days.",
    "AIScore": 45,
    "SL": 335.97,
    "TP": 356.75,
    "SL10": 9.7,
    "TP10": 10.3
  },
  {
    "ticker": "VRTX",
    "name": "Vertex Pharmaceuticals",
    "marketCap": 107948154880,
    "revenueGrowth": 0.11,
    "debtToEquity": 10.594,
    "trailingPE": 29.587492,
    "momentum_2m": 0.08742705393835037,
    "momentum_1w": -0.030309319855620798,
    "FundamentalFilterRating": 66,
    "price": 421.0299987792969,
    "RSI (14)": 50.82,
    "EMA (20)": 425.79,
    "MACD (12,26,9)": 2.8397,
    "MACD_Signal (12,26,9)": 2.1985,
    "percent_change": -3.33,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 69.2,
    "AITicker": "Vertex Pharmaceuticals is a biotechnology company focusing on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.",
    "AIComment": "Given the recent market downturn and the neutral sector trend, Vertex Pharmaceuticals presents a risky short-term trading opportunity. The stock's negative momentum over the past week and a 3.33% decline in price further suggest potential volatility. However, positive MACD values indicate some underlying strength, which might limit downside risks.",
    "AIScore": 45,
    "SL": 417.27,
    "TP": 437.87,
    "SL10": 9.91,
    "TP10": 10.4
  },
  {
    "ticker": "INCY",
    "name": "Incyte",
    "marketCap": 19891417088,
    "revenueGrowth": 0.2,
    "debtToEquity": 0.887,
    "trailingPE": 17.17288,
    "momentum_2m": 0.20619047255743128,
    "momentum_1w": -0.06410495385611759,
    "FundamentalFilterRating": 83,
    "price": 101.31999969482422,
    "RSI (14)": 68.46,
    "EMA (20)": 100.45,
    "MACD (12,26,9)": 4.0491,
    "MACD_Signal (12,26,9)": 4.4561,
    "percent_change": -2.47,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 75.0,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 77.7,
    "AITicker": "Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics in oncology and other areas.",
    "AIComment": "Despite Incyte's solid fundamentals, the current market and sector trends suggest caution for short-term trading. The overall market is trending downward with a significant 5-day loss, and although the healthcare sector remains neutral, Incyte's recent price momentum and negative percent change indicate potential volatility. The high RSI also suggests the stock might be overbought, increasing the risk for a short-term pullback.",
    "AIScore": 40,
    "SL": 98.44,
    "TP": 106.39,
    "SL10": 9.72,
    "TP10": 10.5
  },
  {
    "ticker": "ELV",
    "name": "Elevance Health",
    "marketCap": 71239655424,
    "revenueGrowth": 0.123,
    "debtToEquity": 72.823,
    "trailingPE": 12.886762,
    "momentum_2m": 0.02601779703541096,
    "momentum_1w": -0.03436806640970658,
    "FundamentalFilterRating": 66,
    "price": 316.3699951171875,
    "RSI (14)": 46.56,
    "EMA (20)": 326.83,
    "MACD (12,26,9)": -6.1106,
    "MACD_Signal (12,26,9)": -7.341,
    "percent_change": -2.51,
    "TechFilterRating": 75.0,
    "news_sentiment_percent": 66.7,
    "social_sentiment_percent": null,
    "sector": "Healthcare",
    "sector_name": "XLV",
    "market_change_1d": 0.37538357962292324,
    "market_change_5d": -3.0471785979927946,
    "market_change_20d": -0.8544010945476632,
    "market_trend": "down",
    "sector_change_1d": -0.17038764865044964,
    "sector_change_5d": -0.3206422390259922,
    "sector_change_20d": 4.364205826377443,
    "sector_trend": "neutral",
    "OverallRating": 69.2,
    "AITicker": "Elevance Health, formerly known as Anthem, is a healthcare services provider that offers medical benefits to individuals and businesses.",
    "AIComment": "Elevance Health (ELV) shows a negative short-term trading outlook due to its recent performance and market trends. The stock has experienced a decline in momentum over the past week and is trading below its 20-day EMA, indicating bearish sentiment. Additionally, the overall market trend is down, which could further impact the stock negatively in the coming days.",
    "AIScore": 35,
    "SL": 320.29,
    "TP": 329.02,
    "SL10": 10.12,
    "TP10": 10.4
  }
]